Sunday, November 22, 2026 · The Health Policy Podcast
Health Policy Podcast logo

Receive new episodes in your inbox.

Treatment-resistant depression: What it is, how many people it affects and why access policy matters

Four voices from the Health Policy Podcast — a Medicare claims analyst, a psychiatric chief medical officer, a leading depression researcher and a Tennessee psychiatrist — explain what treatment-resistant depression (TRD) is, what it costs patients and Medicare, and where coverage rules and prior authorization shape care.

Health Policy Podcast

The short answer

Treatment-resistant depression (TRD) is major depression that has not improved after multiple treatments; in the clinical literature it is usually defined as two medication trials that did not work. Health Management Associates (HMA) reports that about a third of the 34 million American teens and adults who have depression have TRD, and its analysis of Medicare claims found TRD patients cost the program about $8,000 more per year than patients whose depression is well controlled. Because insurer and Medicare coverage rules, prior authorization and step requirements decide how fast patients reach the next treatment, policy is a central part of the TRD story.

Key facts at a glance

What is treatment-resistant depression?

Doctors use the term for depression that keeps going after standard care. On the Health Policy Podcast, Sauvé, a psychiatrist and chief medical officer at Osmind, said "there is no actual diagnosis called TRD." He said that "in the literature, it is 2 medication trials that haven't been successful for that patient."

The label can sting. "It is the condition itself which is resistant to treatment," Sauvé said, explaining that nobody thinks the patient is resisting.

Dr. Michelle Cochran, a board-certified psychiatrist and Distinguished Fellow of the American Psychiatric Association, made the same point in Patient Daily's coverage: "Patients with depression haven't failed the treatments." She said that reframing is "really important to remove any kind of guilt or any stigma about the illness." Her closing message on the podcast was that "depression is a treatable biological condition. It's not a personal failure."

How many people are affected?

No single number captures TRD, because it is not a stand-alone diagnosis. Two figures help frame it:

For those who do, the illness can last years. "Historically for me for the last 15 years, it's more like 8 medication trials that have not been successful for the patient," Sauvé said. "These people usually have been suffering from depression without really any significant breaks for a good 10, if not 20 years."

Getting the diagnosis right

Not every case labeled TRD is what it seems. A. John Rush, MD, who has researched depression for about 50 years, said on the Health Policy Podcast that when he ran a specialty clinic for patients referred with TRD, "One of the things we found is that a number of these individuals had not been properly diagnosed."

Patient Daily reported that Rush was the lead investigator of the National Institute of Mental Health's STAR*D trial. Rush described other missed causes too: "Sometimes their depression is caused by a concomitant medication that's not recognized."

He also pointed to a structural issue in care. "Realize that doctors recommend what they do," Rush said. "If you see a primary care doctor, you're not going to get neuromodulation. You see a TMS doctor, you're not going to get psychotherapy. You see a psychotherapy doctor, you're not going to get medication typically. It is just the way our healthcare system is." Asked about matching patients to treatments, he said, "It is still a trial and error, trial and error kind of approach."

What TRD costs patients, employers and Medicare

HMA's Mark Desmarais said his firm compared Medicare patients with well-controlled depression to patients whose depression was not well controlled. "What we found was that individuals with TRD cost the system about $8,000 more each year than those patients whose depression is well managed," Desmarais said on the podcast.

He said the cost is not just prescriptions: "These folks are visiting the hospital more often, visiting the doctor more often. They're really suffering."

The burden reaches beyond the clinic. In Patient Daily's report on the discussion, Sauvé described "presenteeism," where people keep working but struggle. "We're not missing work, we're not on disability, but we're not moving as fast as we should be," he said. "Errors are propagating at work. There's cost associated with that."

Sauvé also said that over time "the comorbidity are piling up." In his words, it is not only the cost of antidepressants, "but it's the cost of potential hospitalizations. But then it's also a cost of medications for metabolic syndrome and maybe ultimately diabetes."

Why delays happen: prior authorization and payer rules

Both clinicians on the podcast pointed to coverage rules. Sauvé, quoted by DC News Line, said that when Osmind asks clinics about their biggest pain point, "everybody probably just universally says in unison, prior authorization."

He described the wait: "you start that process and it could be 1 week, 2 weeks, 3 weeks, 4 weeks waiting for that treatment to start." Meanwhile, he said, "this person is continuing to suffer with their illness."

Cochran, in Patient Daily's coverage of her episode, said insurers "want to restrict clinicians like myself or their patients to these really rigid, very linear protocol limits." She said she has seen delays do harm: "I've seen people who their symptoms worsen. I've seen people have to go in the hospital while they're waiting on treatment."

She also said the cost of delay spreads. "It costs the whole system to delay giving access to these treatments," Cochran said.

Where policy fits

Guests offered several policy angles, each in their own words:

  • Early access can matter financially. Sauvé said that "those treatments may look more expensive on the surface, but if you move to those treatments early in the course, it is highly, highly likely that you're saving much, much, much more than being spent by moving to some kind of intervention after the second medication trial."
  • Enforcement of parity laws. Cochran, quoted by the Nashville Standard, said: "We have wonderful parity laws. Unfortunately, we don't have any enforcement."
  • Aligning payer policies. Cochran said she would like commercial, Medicare and Medicaid policies to stay within "research-driven consensus guidelines" instead of capping the number of treatments or dollars. She noted that in Tennessee, "We've gotten prior authorization reforms, but there really is a lot of work left to do."
  • Open doors. Desmarais said that if policymakers "help create open doors that would lead to solutions for patients, we might also have a positive impact on healthcare spending in America."

Medicare coverage rules are one lever. According to CMS, its national coverage determination for vagus nerve stimulation, effective Feb. 15, 2019, covers FDA-approved devices for TRD only through coverage with evidence development in CMS-approved studies.

On the Health Policy Podcast, Rush said "the 2 major advances are TMS ... And the other is vagus nerve stimulation." Citing the RECOVER trial, he said that when the treatment works, "it keeps on working 80% of the time out to 2 years."

Frequently asked questions

What is treatment-resistant depression?

Treatment-resistant depression, or TRD, is depression that has not improved after multiple treatments. In the clinical literature it is usually defined as two unsuccessful medication trials, Sauvé said on the Health Policy Podcast, and it is not a separate diagnosis in the DSM.

How many people have treatment-resistant depression?

HMA's analysis found that about a third of the 34 million American teens and adults who have depression have TRD. HMA's report describes TRD as affecting nearly one in three people with major depressive disorder.

How much more does treatment-resistant depression cost Medicare?

HMA's analysis of Medicare claims found about $8,000 more per patient per year, or roughly 21% more, than for matched patients with well-controlled depression, according to Fierce Healthcare. Desmarais said on the podcast that these patients visit hospitals and doctors more often.

How does prior authorization affect treatment-resistant depression care?

Sauvé said prior authorization is the pain point clinics name most often and that approvals can take one to four weeks, as reported by DC News Line. Cochran said delays have led some patients to the hospital, according to Patient Daily.

Does treatment-resistant depression mean the patient failed?

No. Cochran said "Patients with depression haven't failed the treatments" and called depression "a treatable biological condition. It's not a personal failure."

Are all "treatment-resistant" cases truly treatment-resistant?

Not necessarily. Rush said a number of patients referred to his specialty clinic "had not been properly diagnosed," as Patient Daily reported.

What policy changes did the guests discuss?

They discussed faster access to treatment, parity-law enforcement, aligning commercial and public payer rules with consensus guidelines, and prior authorization reform, as covered in the Nashville Standard and DC News Line.

Listen to the episodes

Sources

This article is for general information and is not medical advice. If you or someone you know is in crisis in the United States, call or text 988 to reach the Suicide & Crisis Lifeline.